Literature DB >> 8440303

Identification and characterisation of angiotensin II receptor subtypes in human brain.

J M Barnes1, L J Steward, P C Barber, N M Barnes.   

Abstract

Autoradiographic and homogenate binding studies using the radioligand, [125I]angiotensin II, identified a heterogeneous distribution of specific binding sites (defined by angiotensin II, 1.0 microM) throughout the human forebrain. Highest AT receptor densities were detected in the paraventricular nucleus, median eminence, substantia nigra, putamen and caudate nucleus (2.4, 1.2, 1.0, 0.30 and 0.24 fmol/mg tissue equivalent, respectively). The AT1 receptor antagonist, losartan (1.0 microM) competed for the majority of the specific binding. [125I]Angiotensin II-specific binding (although not consistently above non-specific binding levels) was also detected in various other brain regions (e.g. amygdala, entorhinal cortex, frontal cortex, hippocampus, inferior colliculus, nucleus accumbens, parietal cortex, periaquaductal grey, superior colliculus, striate cortex, temporal cortex, thalamus). In the presence of losartan (1.0 microM), angiotensin II, saralasin, losartan and PD123177 competed for [125I]angiotensin II binding to membranes prepared from the cerebellum or substantia nigra with a rank order of affinity; angiotensin II = saralasin > PD123177 > losartan. In the presence of PD123177 (1.0 microM), the rank order of affinity of losartan and PD123177 was reversed. These studies indicate the presence of both AT1 and AT2 receptor subtypes within various regions of the human forebrain.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8440303     DOI: 10.1016/0014-2999(93)90558-y

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

1.  Human brain contains a novel non-AT1, non-AT2 binding site for active angiotensin peptides.

Authors:  Vardan T Karamyan; Craig A Stockmeier; Robert C Speth
Journal:  Life Sci       Date:  2008-07-22       Impact factor: 5.037

Review 2.  The Angiotensin AT2 Receptor: From a Binding Site to a Novel Therapeutic Target.

Authors:  U Muscha Steckelings; Robert E Widdop; Edward D Sturrock; Lizelle Lubbe; Tahir Hussain; Elena Kaschina; Thomas Unger; Anders Hallberg; Robert M Carey; Colin Sumners
Journal:  Pharmacol Rev       Date:  2022-10       Impact factor: 18.923

3.  Type-1 angiotensin receptors are expressed and transported in motor and sensory axons of rat sciatic nerves.

Authors:  Hui Tang; Jaroslav Pavel; Juan M Saavedra; Stephen Brimijoin
Journal:  Neuropeptides       Date:  2009-02-23       Impact factor: 3.286

Review 4.  Brain angiotensin II: new developments, unanswered questions and therapeutic opportunities.

Authors:  Juan M Saavedra
Journal:  Cell Mol Neurobiol       Date:  2005-06       Impact factor: 5.046

Review 5.  Renin angiotensin system and its role in biomarkers and treatment in gliomas.

Authors:  Alexander Perdomo-Pantoja; Sonia Iliana Mejía-Pérez; Liliana Gómez-Flores-Ramos; Montserrat Lara-Velazquez; Cordelia Orillac; Juan Luis Gómez-Amador; Talia Wegman-Ostrosky
Journal:  J Neurooncol       Date:  2018-02-16       Impact factor: 4.130

6.  Ability of angiotensin II to modulate striatal dopamine release via the AT1 receptor in vitro and in vivo.

Authors:  D C Brown; L J Steward; J Ge; N M Barnes
Journal:  Br J Pharmacol       Date:  1996-05       Impact factor: 8.739

7.  Collicular Hyperactivation in Patients with COVID-19: A New Finding on Brain MRI and PET/CT.

Authors:  A Chammas; C Bund; F Lersy; J-C Brisset; F-D Ardellier; S Kremer; I J Namer
Journal:  AJNR Am J Neuroradiol       Date:  2021-05-20       Impact factor: 4.966

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.